An innovative approach to overcoming PD-1 resistance: Combined TIGIT blockade with nanophotothermal therapy DOI
Xi Wang, Yu Wang,

Qihang Zhao

et al.

Applied Materials Today, Journal Year: 2024, Volume and Issue: 41, P. 102437 - 102437

Published: Sept. 19, 2024

Language: Английский

The World of Immunotherapy Needs More Than PD-1/PD-L1—Two of the New Kids on the Block: LAG-3 and TIGIT DOI Creative Commons
João Martins Gama, Paulo Ricardo Teixeira, Rui Caetano Oliveira

et al.

Onco, Journal Year: 2024, Volume and Issue: 4(3), P. 116 - 130

Published: July 1, 2024

Immunotherapy has paved the way for development of solid tumor new treatments in last decade. The approval immune checkpoint inhibitors such as anti PD-1/PD-L1 provided a revolution with optimal results. However, considerable proportion patients experience adverse therapeutic effects, and up to 50% may develop secondary resistance first three five years. This prompted need identifying targets immunotherapy that have good tolerance biosafety and, course, tumoral response, either alone or combination. Two these are Lymphocyte-activation gene 3 (LAG-3) T cell immunoglobulin ITIM domain (TIGIT). They responsible several interactions system, prompting an immunosuppressive phenotype microenvironment. Both LAG-3 TIGIT can be druggable, combination anti-PD-1/PD-L1, rather safe profiles making them attractive. In this review, we highlight some mechanisms their detection by immunohistochemistry, providing insight into use clinical setting.

Language: Английский

Citations

1
Pancreatic ductal adenocarcinoma microenvironment: Soluble factors and cancer associated fibroblasts as modulators of NK cell functions DOI Creative Commons
Simona Carlomagno, Chiara Setti, Fulvia Ortolani

et al.

Immunology Letters, Journal Year: 2024, Volume and Issue: 269, P. 106898 - 106898

Published: July 15, 2024

Pancreatic Ductal Adenocarcinoma (PDAC) is the most frequent pancreatic cancer and represents one of aggressive human neoplasms. Typically identified at advance stage disease, PDAC tumors are unresectable resistant to standard therapies. The immunosuppressive microenvironment in impedes tumor control but a greater understanding complex stromal interactions within (TME) development strategies capable restoring antitumor effector immune responses could be crucial fight this its spread. Natural Killer (NK) cells play role immunosurveillance represent an attractive target for immunotherapies, both as cell therapy pharmaceutical target. This review describes some components TME (collagens, soluble factors fibroblasts) that can influence presence, phenotype function NK patients tissue. focused overview highlights therapeutic relevance dissecting composition define new cell-based immunotherapies improve treatment PDAC.

Language: Английский

Citations

1
Next generation immune checkpoints DOI

Natalia Muñoz Perez,

Kirsten Moziak,

Allison Martin

et al.

Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 1, 2024

Language: Английский

Citations

0
Target therapy of TIGIT; a novel approach of immunotherapy for the treatment of colorectal cancer DOI
Jing Sun,

Yan Tian,

Changqing Yang

et al.

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 19, 2024

Language: Английский

Citations

0
An innovative approach to overcoming PD-1 resistance: Combined TIGIT blockade with nanophotothermal therapy DOI
Xi Wang, Yu Wang,

Qihang Zhao

et al.

Applied Materials Today, Journal Year: 2024, Volume and Issue: 41, P. 102437 - 102437

Published: Sept. 19, 2024

Language: Английский

Citations

0